 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...131132133134135136137138139140141...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial termination: Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer (clinicaltrials.gov) - Oct 28, 2013
P=N/A, N=2, Terminated, Sponsor: Georgetown University
Recruiting --> Terminated; low accruals--2 patients were enrolled in over a year
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment change: Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer (clinicaltrials.gov) - Oct 28, 2013
P=N/A, N=2, Terminated, Sponsor: Georgetown University
Recruiting --> Terminated; low accruals--2 patients were enrolled in over a year N=18 --> 2
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: TYKERB-ITUX 1: Lapatinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - Oct 28, 2013
P1, N=22, Completed, Sponsor: Georgetown University
N=18 --> 2 N=18 --> 22
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: TYKERB-ITUX 1: Lapatinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - Oct 28, 2013
P1, N=22, Completed, Sponsor: Georgetown University
N=18 --> 22 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion, Metastases: Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. (clinicaltrials.gov) - Oct 28, 2013
P2, N=54, Completed, Sponsor: Regione Lombardia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - Oct 24, 2013
P1, N=198, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 24, 2013
P2, N=50, Completed, Sponsor: Stanford University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: ARTSCANIII: A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. (clinicaltrials.gov) - Oct 23, 2013
P3, N=618, Recruiting, Sponsor: Lund University Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, IO biomarker, Metastases: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2013
P1, N=21, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Completed Initiation date: Sep 2008 --> Jan 2009
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, IO biomarker, Metastases: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2013
P1, N=21, Terminated, Sponsor: EMD Serono
Initiation date: Sep 2008 --> Jan 2009 N=30 --> 21
- Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors (clinicaltrials.gov) - Oct 14, 2013
P1, N=16, Recruiting, Sponsor: Roger Williams Medical Center
N=30 --> 21 Active, not recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Oct 10, 2013
P2, N=50, Completed, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Recruiting Recruiting --> Completed
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Nerlynx (neratinib) / Puma
New P1/2 trial, Metastases: Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 8, 2013
P1/2, N=70, Recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: CERTO: Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 23, 2013
P2, N=232, Completed, Sponsor: Merck KGaA
Recruiting --> Completed N=164 --> 232
- || Nimoral (nimorazole) / Norgine, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) (clinicaltrials.gov) - Sep 23, 2013
P3, N=470, Not yet recruiting, Sponsor: Christie Hospital NHS Foundation Trust
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: CERTO: Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 23, 2013
P2, N=232, Completed, Sponsor: Merck KGaA
N=164 --> 232 Active, not recruiting --> Completed
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opaxio (paclitaxel poliglumex) / SOBI
Enrollment change, Metastases: A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer (clinicaltrials.gov) - Sep 11, 2013
P1/2, N=60, Recruiting, Sponsor: State University of New York - Upstate Medical University
Active, not recruiting --> Completed N=40 --> 60
- | Avastin (bevacizumab) / Roche, dulanermin (AMG 951) / Amgen, Roche
Trial completion, Combination therapy, Metastases: A Study of Dulanermin Administered in Combination With Camptosar (clinicaltrials.gov) - Sep 8, 2013
P1, N=42, Completed, Sponsor: Genentech
N=40 --> 60 Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: EMR62202-512: A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) (clinicaltrials.gov) - Sep 4, 2013
P=N/A, N=215, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed N=300 --> 215
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: EMR62202-512: A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) (clinicaltrials.gov) - Sep 4, 2013
P=N/A, N=215, Active, not recruiting, Sponsor: Merck KGaA
N=300 --> 215 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial, Metastases: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (clinicaltrials.gov) - Sep 3, 2013
P1, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
- cixutumumab (IMC A12) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 3, 2013
P2, N=140, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion, Combination therapy: AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer (clinicaltrials.gov) - Aug 28, 2013
P1, N=10, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Active, not recruiting --> Completed
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial: Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT (clinicaltrials.gov) - Aug 27, 2013
P3, N=40, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT (clinicaltrials.gov) - Aug 27, 2013
P3, N=40, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Aug 26, 2013
P2, N=108, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| gedatolisib (PF-05212384) / Celcuity
New P2 trial, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2013
P2, N=159, Recruiting, Sponsor: Pfizer
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Surgery: Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis (clinicaltrials.gov) - Aug 14, 2013
P2, N=39, Recruiting, Sponsor: Korea Cancer Center Hospital
- ||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Metastases: AlloStim (clinicaltrials.gov) - Aug 13, 2013
P2/3, N=208, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Active, not recruiting --> Completed Initiation date: Apr 2013 --> Jan 2014
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 13, 2013
P2, N=30, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Apr 2013 --> Jan 2014 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (clinicaltrials.gov) - Aug 12, 2013
P2, N=8, Terminated, Sponsor: Austrian Breast & Colorectal Cancer Study Group
Recruiting --> Active, not recruiting N=132 --> 8
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: REPLACE: Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Aug 9, 2013
P2, N=60, Completed, Sponsor: Sun Yat-sen University
N=132 --> 8 Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
New P2 trial, Metastases: Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 7, 2013
P2, N=75, Recruiting, Sponsor: UNICANCER
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change, Combination therapy: Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma (clinicaltrials.gov) - Aug 5, 2013
P3, N=150, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Recruiting --> Completed N=200 --> 150
- Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Aug 1, 2013
P1/2, N=63, Recruiting, Sponsor: howard safran
N=200 --> 150 N=25 --> 63
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Chemoradiation Treatment for Head and Neck Cancer (clinicaltrials.gov) - Jul 31, 2013
P2, N=60, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
N=25 --> 63 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Clinical trial in patients with metastatic colorectal Cancer to evaluate the response of removable liver metastases after treatment with Cetuximab (Erbitux). Ensayo Cl (EUDRACT) - Jul 29, 2013
P2, N=80, Ongoing, Sponsor: ACROSS: Associaci
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery, Metastases: Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jul 29, 2013
P3, N=420, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer (clinicaltrials.gov) - Jul 28, 2013
P2, N=108, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
New P3 trial, Metastases: STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2013
P3, N=474, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 24, 2013
P1/2, N=42, Recruiting, Sponsor: Ahmad Wehbe
Recruiting --> Active, not recruiting Initiation date: Nov 2012 --> Apr 2013
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 24, 2013
P1/2, N=42, Recruiting, Sponsor: Ahmad Wehbe
Initiation date: Nov 2012 --> Apr 2013 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma (clinicaltrials.gov) - Jul 23, 2013
P2, N=35, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer (clinicaltrials.gov) - Jul 22, 2013
P2, N=39, Completed, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Cetuximab, Paclitaxel, Carboplatin And Radiation For Esophageal, Gastroesophageal Junction And Gastric Cancer (clinicaltrials.gov) - Jul 18, 2013
P2, N=60, Completed, Sponsor: Brown University
- ||| dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment closed, Combination therapy, Metastases: A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) (clinicaltrials.gov) - Jul 14, 2013
P2a, N=70, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
New P2 trial, Metastases: Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects (clinicaltrials.gov) - Jul 2, 2013
P2, N=41, Recruiting, Sponsor: Armando Santoro, MD
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Sutent (sunitinib) / Pfizer
Trial termination, Metastases: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Active, not recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Sutent (sunitinib) / Pfizer
Trial initiation date, Metastases: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Initiation date: Jul 2007 --> Jul 2008
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment open, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P2, N=175, Recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Initiation date: Jul 2007 --> Jul 2008 Not yet recruiting --> Recruiting